OTCPK:TRVN - Post by User
Post by
GolongGekkoon Feb 22, 2017 7:35pm
116 Views
Post# 25880299
Allergan has history with TRVN...
Allergan has history with TRVN... Allergan's Saunders: No interest in Valeant
Speaking to Bloomberg, Allergan (NYSE:AGN) CEO Brett Saunders says Valeant (NYSE:VRX) isn't a strategic fit and isn't a growth asset.
"We like things with pipeline and innovation. I’m not aware of any real pipeline or innovation ... I don't want to buy a turnaround situation."
As for Bristol-Myers (NYSE:BMY), everybody is taking a look thanks to reports Carl Icahn has taken a stake, he says, but it would be a "high hurdle" for Allergan.
Allergan, he says, has "no strategic imperative" to do a large deal, but instead would rather look for opportunities in focus areas like medical aesthetics and dermatology, eye care, central nervous system, and gastroenterology. He also sees possibilities in skin quality and hair restoration.